Aligos Therapeutics (ALGS) closed at $4.07 on November 6, 2026, down 9.8% from the previous close, on volume of 101,235 shares (30-day average 32,880).
Data as of November 6, 2026.
Aligos Therapeutics GAAP EPS of -$2.09 beats by $0.19, revenue of $2.83M misses by $2.71M
Seeking Alpha News (Fri, 6-Nov 8:46 AM ET)
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
Globe Newswire (Fri, 6-Nov 8:00 AM ET)
Aligos Therapeutics Presents Positive Data at The Liver Meeting 2026
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting 2026
Globe Newswire (Mon, 5-Oct 4:05 PM ET)
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
Globe Newswire (Wed, 12-Aug 4:05 PM ET)
Aligos Secures $25M Upfront and Eyes $420M in Milestones from Greater China Hepatitis B Deal
Market Chameleon (Tue, 7-Jul 3:06 AM ET)
Aligos Therapeutics Secures FDA Fast Track, Advances HBV Pipeline and Strengthens China Partnership
Market Chameleon (Fri, 8-May 3:08 AM ET)
Market Chameleon (Thu, 16-Apr 7:51 AM ET)
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.
As of November 6, 2026, ALGS stock price declined to $4.07 with 101,235 million shares trading.
ALGS has a beta of 1.86, meaning it tends to be more sensitive to market movements. ALGS has a correlation of 0.06 to the broad based SPY ETF.
ALGS has a market cap of $25.42 million. This is considered a Sub-Micro Cap stock.
Last quarter Aligos Therapeutics reported $0 in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-19 million and exceeded earnings estimates by $1.14.
In the last 3 years, ALGS traded as high as $46.80 and as low as $3.76.
The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, IWC, DFMC, DFAS.
ALGS has underperformed the market in the last year with a price return of -42.7% while the SPY ETF gained +10.8%. ALGS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.1% and -14.9%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
ALGS support price is $4.21 and resistance is $4.81 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS shares will trade within this expected range on the day.
